Alpha-Lipoic Acid (ALA) for Parkinson's Disease
Also known as: ALA, Thioctic acid, R-lipoic acid
ALA's mitochondrial support and iron chelation properties target core pathological mechanisms in Parkinson's substantia nigra.
Mechanism of Action
ALA enhances Complex I activity (deficient in PD), chelates excess iron in the substantia nigra (which catalyzes dopamine oxidation), and restores glutathione levels. It also reduces α-synuclein aggregation through modulation of oxidative stress-driven misfolding.
General mechanism: Universal antioxidant and mitochondrial cofactor. Regenerates other antioxidants, chelates metals, enhances pyruvate dehydrogenase activity.
Current Evidence
Preclinical models show dopaminergic neuron protection. Clinical data limited to small studies showing improved motor scores. Combination with standard PD therapy explored.
Clinical Status: Preclinical and early clinical. Available as supplement.
Safety Profile
Very safe orally. IV use requires medical supervision. Hypoglycemia risk in diabetics. Rare: autoimmune insulin syndrome in susceptible individuals.
Key Research Questions
- Can ALA slow iron-mediated dopaminergic neurodegeneration?
- What is the interaction between ALA and levodopa?